| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.
|
N Engl J Med
|
2005
|
33.60
|
|
2
|
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.
|
N Engl J Med
|
2016
|
8.53
|
|
3
|
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
|
J Clin Oncol
|
2007
|
7.73
|
|
4
|
Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03.
|
J Clin Oncol
|
2009
|
5.69
|
|
5
|
Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08.
|
J Clin Oncol
|
2010
|
4.81
|
|
6
|
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
|
J Clin Oncol
|
2005
|
4.77
|
|
7
|
Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.
|
J Clin Oncol
|
2005
|
4.66
|
|
8
|
Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer.
|
J Clin Oncol
|
2012
|
4.57
|
|
9
|
DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.
|
J Natl Cancer Inst
|
2011
|
4.08
|
|
10
|
Real-world performance of HER2 testing--National Surgical Adjuvant Breast and Bowel Project experience.
|
J Natl Cancer Inst
|
2002
|
3.99
|
|
11
|
Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.
|
J Clin Oncol
|
2009
|
3.38
|
|
12
|
Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin.
|
J Clin Oncol
|
2010
|
3.19
|
|
13
|
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value.
|
Clin Cancer Res
|
2012
|
3.07
|
|
14
|
Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.
|
J Clin Oncol
|
2006
|
2.81
|
|
15
|
Body mass index and outcomes in patients who receive adjuvant chemotherapy for colon cancer.
|
J Natl Cancer Inst
|
2006
|
2.77
|
|
16
|
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009.
|
J Natl Cancer Inst
|
2010
|
2.59
|
|
17
|
End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
|
J Clin Oncol
|
2007
|
2.41
|
|
18
|
Initial safety report of NSABP C-08: A randomized phase III study of modified FOLFOX6 with or without bevacizumab for the adjuvant treatment of patients with stage II or III colon cancer.
|
J Clin Oncol
|
2009
|
2.34
|
|
19
|
Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.
|
J Clin Oncol
|
2012
|
2.19
|
|
20
|
Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database.
|
J Clin Oncol
|
2013
|
1.62
|
|
21
|
FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer.
|
Cancer Invest
|
2008
|
1.56
|
|
22
|
Conditional survival and the choice of conditioning set for patients with colon cancer: an analysis of NSABP trials C-03 through C-07.
|
J Clin Oncol
|
2010
|
1.47
|
|
23
|
Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial.
|
J Clin Oncol
|
2012
|
1.46
|
|
24
|
Biomarker discovery for colon cancer using a 761 gene RT-PCR assay.
|
BMC Genomics
|
2007
|
1.46
|
|
25
|
Exploring and validating surrogate endpoints in colorectal cancer.
|
Lifetime Data Anal
|
2008
|
1.34
|
|
26
|
Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.
|
Ann Surg Oncol
|
2010
|
1.27
|
|
27
|
Prevalence of burnout in the u.s. Oncology community: results of a 2003 survey.
|
J Oncol Pract
|
2005
|
1.27
|
|
28
|
Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis.
|
Cancer
|
2007
|
1.25
|
|
29
|
Body mass index at diagnosis and survival among colon cancer patients enrolled in clinical trials of adjuvant chemotherapy.
|
Cancer
|
2013
|
1.25
|
|
30
|
Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set.
|
J Clin Oncol
|
2009
|
1.24
|
|
31
|
Multinational study of pneumococcal serotypes causing acute otitis media in children.
|
Pediatr Infect Dis J
|
2002
|
1.22
|
|
32
|
Health-related quality of life in axillary node-negative, estrogen receptor-negative breast cancer patients undergoing AC versus CMF chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel Project B-23.
|
Breast Cancer Res Treat
|
2004
|
1.15
|
|
33
|
NIH state-of-the-science conference statement: diagnosis and management of ductal carcinoma in situ (DCIS).
|
NIH Consens State Sci Statements
|
2009
|
1.10
|
|
34
|
Quality of life in operable colon cancer patients receiving oral compared with intravenous chemotherapy: results from National Surgical Adjuvant Breast and Bowel Project Trial C-06.
|
J Clin Oncol
|
2007
|
1.07
|
|
35
|
Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group.
|
J Cancer Surviv
|
2009
|
1.04
|
|
36
|
A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials.
|
Clin Trials
|
2012
|
0.99
|
|
37
|
Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.
|
J Clin Oncol
|
2011
|
0.98
|
|
38
|
Toward progression-free survival as a primary end point in advanced colorectal cancer.
|
J Clin Oncol
|
2007
|
0.97
|
|
39
|
End points in advanced colon cancer clinical trials: a review and proposal.
|
J Clin Oncol
|
2007
|
0.95
|
|
40
|
Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04.
|
Ann Surg
|
2015
|
0.94
|
|
41
|
Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01.
|
Cancer
|
2012
|
0.93
|
|
42
|
Using cure models and multiple imputation to utilize recurrence as an auxiliary variable for overall survival.
|
Clin Trials
|
2011
|
0.90
|
|
43
|
Routine preventive care and cancer surveillance in long-term survivors of colorectal cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol LTS-01.
|
J Clin Oncol
|
2010
|
0.89
|
|
44
|
Defective mismatch repair and benefit from bevacizumab for colon cancer: findings from NSABP C-08.
|
J Natl Cancer Inst
|
2013
|
0.89
|
|
45
|
Comparison of outcomes after fluorouracil-based adjuvant therapy for stages II and III colon cancer between 1978 to 1995 and 1996 to 2007: evidence of stage migration from the ACCENT database.
|
J Clin Oncol
|
2013
|
0.89
|
|
46
|
Colon cancer mutation: prognosis/prediction--response.
|
Clin Cancer Res
|
2013
|
0.80
|
|
47
|
Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set.
|
J Clin Oncol
|
2012
|
0.79
|
|
48
|
The predictive and prognostic value of sex in early-stage colon cancer: a pooled analysis of 33,345 patients from the ACCENT database.
|
Clin Colorectal Cancer
|
2013
|
0.78
|
|
49
|
Multiagent regimens for metastatic colorectal cancer: if some is good, more must be better.
|
J Natl Cancer Inst
|
2010
|
0.75
|